BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 32616304)

  • 1. The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types.
    Varga C; Dorbala S; Lousada I; Polydefkis MJ; Wechalekar A; Maurer MS; Comenzo RL
    Blood Rev; 2021 Jan; 45():100720. PubMed ID: 32616304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Amyloidosis Treatment.
    Stern LK; Patel J
    Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the Treatment of Cardiac Amyloidosis.
    Macedo AVS; Schwartzmann PV; de Gusmão BM; Melo MDT; Coelho-Filho OR
    Curr Treat Options Oncol; 2020 Apr; 21(5):36. PubMed ID: 32328845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Care of Patients with Cardiac Amyloidosis.
    Itzhaki Ben Zadok O; Kornowski R
    Acta Haematol; 2020; 143(4):343-351. PubMed ID: 32408301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
    Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
    Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
    Ruberg FL; Maurer MS
    JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF; Hahn K
    Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac transthyretin amyloidosis.
    Dungu JN; Anderson LJ; Whelan CJ; Hawkins PN
    Heart; 2012 Nov; 98(21):1546-54. PubMed ID: 22888163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy.
    Hänselmann A; Berliner D; Bauersachs J; Bavendiek U
    Herz; 2022 Aug; 47(4):324-331. PubMed ID: 35674775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
    Di Lisi D; Di Stefano V; Brighina F; Galassi AR; Novo G
    Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.
    Kittleson MM; Maurer MS; Ambardekar AV; Bullock-Palmer RP; Chang PP; Eisen HJ; Nair AP; Nativi-Nicolau J; Ruberg FL;
    Circulation; 2020 Jul; 142(1):e7-e22. PubMed ID: 32476490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of biomarkers to diagnose and manage cardiac amyloidosis.
    Castiglione V; Franzini M; Aimo A; Carecci A; Lombardi CM; Passino C; Rapezzi C; Emdin M; Vergaro G
    Eur J Heart Fail; 2021 Feb; 23(2):217-230. PubMed ID: 33527656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis.
    Swiger KJ; Friedman EA; Brittain EL; Tomasek KA; Huang S; Su YR; Sawyer DB; Lenihan DJ
    Amyloid; 2016 Dec; 23(4):242-248. PubMed ID: 27809600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloidosis in Heart Failure.
    Ihne S; Morbach C; Obici L; Palladini G; Störk S
    Curr Heart Fail Rep; 2019 Dec; 16(6):285-303. PubMed ID: 31782077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
    Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R
    ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardiac amyloidosis: State of art in 2022].
    Oghina S; Delbarre MA; Poullot E; Belhadj K; Fanen P; Damy T
    Rev Med Interne; 2022 Sep; 43(9):537-544. PubMed ID: 35870985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.